Navigation Links
SENOMYX, INC. FIRST QUARTER 2009 EARNINGS CONFERENCE CALL SCHEDULED FOR MAY 7, 2009
Date:4/23/2009

SAN DIEGO, CA, April 23, 2009 /PRNewswire-FirstCall/ -- Senomyx, Inc. (Nasdaq: SNMX) will release its first quarter 2009 financial results on Thursday, May 7, 2009 before the opening of the U.S. financial markets. The Company will also host a conference call with a live Internet broadcast that will provide a corporate update and a review of its first quarter results on the same day at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time).

To participate in the live conference call, U.S. residents should dial 888-679-8033, and international callers should dial 617-213-4846, at least 10 minutes prior to the call start time. The participant passcode for this conference call is 16029924. Participants may pre-register for the call at anytime, including up to and after the call start time, at https://www.theconferencingservice.com/prereg/key.process?key=P8FDK4BBQ. Pre-registrants will be issued a pin number to use when dialing into the live call, which will provide quick access to the conference.

To access the live Internet broadcast or a subsequent archived recording, please log onto the Investor Relations section of Senomyx's website at http://investor.senomyx.com. The archived webcast will be available for 30 days following the presentation. Please connect to Senomyx's website prior to the start of the webcast to ensure adequate time to download any software that may be necessary.

About Senomyx, Inc.

Senomyx is a leading company using proprietary taste receptor technologies to discover and develop novel flavor ingredients in the savory, sweet, salt, bitter, and cooling areas. Senomyx has entered into product discovery and development collaborations with seven of the world's foremost food, beverage, and ingredient supply companies: Ajinomoto Co., Inc., Cadbury plc, Campbell Soup Company, The Coca-Cola Company, Firmenich SA, Nestle SA, and Solae. Nestle is currently marketing products that contain one of Senomyx's flavor ingredients. For more information, please visit www.senomyx.com.

    Contact:
    Gwen Rosenberg
    Senomyx, Inc.
    Vice President, Investor Relations & Corporate Communications
    858-646-8369
    gwen.rosenberg@senomyx.com


'/>"/>
SOURCE Senomyx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. SENOMYX, INC. fourth quarter AND FISCAL YEAR-END 2008 Earnings conference call scheduled for February 12, 2009
2. SENOMYX, INC. THIRD QUARTER 2008 EARNINGS CONFERENCE CALL SCHEDULED FOR NOVEMBER 6, 2008
3. Insmed to Host First Quarter 2009 Conference Call
4. Essilor : 2009 First Quarter Report
5. Human Genome Sciences to Sponsor Conference Call to Discuss First Quarter 2009 Financial Results
6. Sangamo BioSciences Announces First Quarter 2009 Conference Call and Webcast
7. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
8. SiliconSky GPS Designs First AGPS-Enabled Asthma Inhaler for Landmark Research Program
9. Z Therapy Is The First In North Texas To Offer Revolutionary Treatment Option For Neck Pain Sufferers
10. NxStage to Report First Quarter 2009 Financial Results
11. InterMune to Release First Quarter Financial Results on April 30
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):